Progress in immunosuppression;Fortschritte in der Immunsuppression

Chirurg

Volumn 79, Issue 2, 2008, Pages 149-156

  Strassburg, C P ^a   Bahr, M J ^a   Becker, T ^a   Klempnauer, J ^a   Manns, M P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Alloimmunity; Antimetabolites; Calcineurin inhibitor; T lymphocyte; Tolerance

Indexed keywords

ALLOANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BLOOD; DRUG EFFECT; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; LIVER TRANSPLANTATION; LYMPHOCYTE ACTIVATION; PROGNOSIS; SIGNAL TRANSDUCTION;

GRAFT REJECTION; HUMANS; IMMUNOLOGIC TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; LIVER TRANSPLANTATION; LYMPHOCYTE ACTIVATION; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 39149085647     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-007-1456-8     Document Type: Article

References (48)

1. Bahr MJ, Beckermann JG, Rifai K et al. (2005) Retrospective analysis of the impact of immunosuppression on the course of recurrent Hepatitis C after liver transplantation. Transplant Proc 37: 1703-1704
2. Beaudreuil S, Samuel D, Rouas-Freiss N et al. (2007) New aspect of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation? Transpl Immunol 17: 98-107
3. Benseler V, Mccaughan GW, Schlitt HJ et al. (2007) The liver: a special case in transplantation tolerance. Semin Liver Dis 27: 194-213
4. Berenguer M, Crippin J, Gish R et al. (2003) A model to predict severe HCV-related disease following liver transplantation. Hepatology 38: 34-41
5. Berenguer M, Ferrell L, Watson J et al. (2000) HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 32: 673-684
6. Berenguer M, Prieto M, Rayon JM et al. (2000) Natural history of clinically compensated Hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 32: 852-858
7. Berenguer M, Royuela A, Zamora J (2007) Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 13: 21-29
8. Bishop GA, Mccaughan GW (2001) Immune activation is required for the induction of liver allograft tolerance: implications for immunosuppressive therapy. Liver Transpl 7: 161-172
9. Calmus Y, Scheele JR, Gonzalez-Pinto I et al. (2002) Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 8: 123-131
10. Calne RY, White DJ, Thiru S et al. (1978) Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2: 1323-1327
11. Decaens T, Roudot-Thoraval F, Bresson-Hadni S et al. (2006) Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients. World J Gastroenterol 12: 7319-7325
12. Dousset B, Hubscher SG, Padbury RT et al. (1993) Acute liver allograft rejection-Is treatment always necessary? Transplantation 55: 529-534
13. Eason JD, Nair S, Cohen AJ et al. (2003) Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 75: 1396-1399
14. Emre S, Gondolesi G, Polat K et al. (2001) Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 7: 220-225
15. Figueras J, Prieto M, Bernardos A et al. (2006) Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. Transpl Int 19: 641-648
16. Filipponi F, Callea F, Salizzoni M et al. (2004) Double-blind comparison of Hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 78: 1488-1495
17. Firpi RJ, Zhu H, Morelli G et al. (2006) Cyclosporine suppresses Hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 12: 51-57
18. Hirose R, Vincenti F (2006) Immunosuppression: today, tomorrow, and withdrawal. Semin Liver Dis 26: 201-210
19. Hong M, Angus PW, Jones RM et al. (2005) Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction. Clin Transplant 19: 193-198
20. Houssin D, Gigou M, Franco D et al. (1980) Specific transplantation tolerance induced by spontaneously tolerated liver allograft in inbred strains of rats. Transplantation 29: 418-419
21. Inoue K, Sekiyama K, Yamada M et al. (2003) Combined interferon alpha2b and cyclosporin A in the treatment of chronic Hepatitis C: controlled trial. J Gastroenterol 38: 567-572
22. Jain A, Kashyap R, Demetris AJ et al. (2002) A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with Hepatitis C. Liver Transpl 8: 40-46
23. Kamada N, Wight DG (1984) Antigen-specific immunosuppression induced by liver transplantation in the rat. Transplantation 38: 217-221
24. Kato T, Yoshida H, Sadfar K et al. (2005) Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with Hepatitis C: a preliminary report from a prospective randomized study. Transplant Proc 37: 1217-1219
25. Kishimoto K, Dong VM, Sayegh MH (2000) The role of costimulatory molecules as targets for new immunosuppressives in transplantation. Curr Opin Urol 10: 57-62
26. Klintmalm GB, Washburn WK, Rudich SM et al. (2007) Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 13: 1521-1531
27. Koehl GE, Andrassy J, Guba M et al. (2004) Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77: 1319-1326
28. Koehl GE, Gaumann A, Zuelke C et al. (2006) Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used. Transplantation 82: 741-748
29. Lam P, Yoshida A, Brown K et al. (2004) The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Dig Dis Sci 49: 1029-1035
30. Margarit C, Bilbao I, Castells L et al. (2005) A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of Hepatitis C. Transpl Int 18: 1336-1345
31. Morard I, Dumortier J, Spahr L et al. (2007) Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 13: 658-664
32. Mosley JD, Poirier JT, Seachrist DD et al. (2007) Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mol Cancer Ther 6: 2188-2197
33. Nelson DR, Soldevila-Pico C, Reed A et al. (2001) Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe Hepatitis C recurrence after liver transplantation. Liver Transpl 7: 1064-1070
34. Neuberger J (1999) Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl Surg 5: 30-36
35. Neuhaus P, Clavien PA, Kittur D et al. (2002) Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 8: 132-142
36. Ojo AO, Held PJ, Port FK et al. (2003) Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349: 931-940
37. Rebellato LM, Gross U, Verbanac KM et al. (1994) A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 57: 685-694
38. Reich DJ, Clavien PA, Hodge EE (2005) Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation 80: 18-25
39. Rifai K, Kirchner GI, Bahr MJ et al. (2006) A new side effect of immunosuppression: high incidence of hearing impairment after liver transplantation. Liver Transpl 12: 411-415
40. Roche B, Samuel D (2007) Risk factors for Hepatitis C recurrence after liver transplantation. J Viral Hepat [Suppl 1] 14: 89-96
41. Schlitt HJ, Barkmann A, Boker KH et al. (2001) Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 357: 587-591
42. Shenoy S, Hardinger KL, Crippin J et al. (2007) Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 83: 1389-1392
43. Stewart SF, Hudson M, Talbot D et al. (2001) Mycophenolate mofetil monotherapy in liver transplantation. Lancet 357: 609-610
44. Toso C, Meeberg GA, Bigam DL et al. (2007) De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 83: 1162-1168
45. Watashi K, Hijikata M, Hosaka M et al. (2003) Cyclosporin A suppresses replication of Hepatitis C virus genome in cultured hepatocytes. Hepatology 38: 1282-1288
46. Watson CJ, Gimson AE, Alexander GJ et al. (2007) A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 13: 1694-1702
47. Wiesner RH, Shorr JS, Steffen BJ et al. (2005) Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without Hepatitis C. Liver Transpl 11: 750-759
48. Zhu J, Wu J, Frizell E et al. (1999) Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 117: 1198-1204